NCT01218633|CompletedPhase 1
Dose-response Study of Exendin-9,39 on Glucose Metabolism
A Dose-response Study of the Effects of Exendin-9,39 on Glucose Metabolism, Glucagon and Insulin Secretion and on Insulin Action.
Loading search results
A Dose-response Study of the Effects of Exendin-9,39 on Glucose Metabolism, Glucagon and Insulin Secretion and on Insulin Action.
Sponsor study identifier
interventional
11
1 country
1
Study Start
May 2011
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
July 2012
Actual (reported)Study Completion
December 2012
Actual (reported)Multiple studies have examined the effect of endogenous GLP-1 secretions by using a competitive antagonist of GLP-1 - Exendin-9,39 - infused at rates of 300pmol/kg/min. However, the presence of an effect does not necessarily imply that this effect is due to the blockade of the endogenous GLP-1 actions at the receptor. It is possible that the supraphysiologic concentrations of Exendin may have effects of its own. To examine the effect of Exendin on glucose metabolism the investigators propose a dose-response study to determine whether the compound has effects in a dose-dependent fashion.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 2012
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 8, 2010
Actual (reported)October 11, 2010
Actual (reported)May 2011
Date type not reportedThis date has not been verified as actual or estimated.
July 2012
Actual (reported)December 2012
Actual (reported)Insulin Secretion
over 360 minutes of study
glucagon secretion
over 360 minutes of study
saline infused at 30ml/hour
infused @ 1.2pmol/kg/min
Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.
Mayo Clinic
Rochester, Minnesota, 55905, United States
Sathananthan M, Farrugia LP, Miles JM, Piccinini F, Dalla Man C, Zinsmeister AR, Cobelli C, Rizza RA, Vella A. Direct effects of exendin-(9,39) and GLP-1-(9,36)amide on insulin action, beta-cell function, and glucose metabolism in nondiabetic subjects. Diabetes. 2013 Aug;62(8):2752-6. doi: 10.2337/db13-0140. Epub 2013 Apr 1.
Adrian Vella, MD
Mayo Clinic
11 participants (actual enrollment reported by the registry).
First Submitted
October 8, 2010
First Posted
October 11, 2010
Study Start
May 2011
Date type not reportedThis date has not been verified as actual or estimated.
Cardiovascular Analysis of PEM
infused at 30pmol/kg/min
infused @ 300pmol/kg/min
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Primary Completion
July 2012
Actual (reported)Study Completion
December 2012
Actual (reported)Last Updated
January 23, 2013
Record last verified: 2013-01
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: